Exchange: NASDAQ·Updated 07:30 PM EST
MGTX logo

MGTX MeiraGTx Holdings plc

$7.98
$0.16
(1.97%)
Today
Closed $7.98
$0.00
(0.00%)
After Hours
Reported EarningsNov 12
Mkt Cap$779.89M
Vol1.01M

About MGTX

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
41

Bearish Sentiment

How do you feel about MGTX?

Bogy99
$MGTX might be one of the longest stretches we’ve had of no new clinical updates. Aside from 3yr update on P1 Xero data , really nothing else this year. Been busy with financing , but no major commercial updates. I would say we are overdue for some news.
6
Bogy99
$MGTX regarding RIX treatment. “ in the course of my career I have had 4 or 5 experiences where I saw something and said ‘that is freaking awesome ‘ this (MGTX RIX treatment) is something that I have to integrate in my practice “. KOL.
5
Bogy99
$MGTX these low volume sell offs , while very real, are not an indication of how well the company is doing. Complete absence of buyers and a simple 10% over the day seller of this stock causes this nonsense. Today’s massive bond sell off is not helping things nor is the weak XBi tape. I’m not sure where the bottom is for this round of selling but the set up is too good to be on the sidelines. 2027 will be a big year for this stock. We’ve come this far , only good things ahead. First 3 analysts updates today have price targets of $50, $40 and $30. Hold your nose and buy more. That’s what I’m doing. Stay the course !!
5
slinghook67
$MGTX Great news for Ollin but this is pretty remarkable and once again speaks to how significantly undervalued Meira is. Ollin only has 2 assets, one is Phase 1 and the 2nd hasn't officially started Phase 3. And their lead asset, while showing very strong efficacy to date, if approved will enter a brutally competitive market and given that, their peak annual sales potential is falling in the range of $1.5b-$2b. And, they do not own any manufacturing assets. Again, this is fantastic news for Ollin but contrast this purchase price with the totality of Meira's enterprise assets and our current market cap, and one can only imagine what our buyout price will be if Bota-Vec and Xerostomia trend towards regulatory approval. Not to mention Parkinson's & Riboswitch.....
4
slinghook67
$MGTX Curious as to who among us has been buying more Meira shares over the past 60 days given their decline? My hand is raised on that one.... I thought I was done and my position was closed but their current price is once again insanely low and it's too hard to let this opportunity go.
4
MGTX
$MGTX MGTX is like little orphan Annie. Always singing about tomorrow. Hope 2027 will finally be the year…
3
slinghook67
$MGTX Another transaction from earlier today. $1.5b deal value for a single stand-alone preclinical asset. Preclinical. Let that sink in.
2
waterlock
$MGTX I think partially selling the stocks earlier last month is the right thing to do. Still reading the filing now but got a very quick question. Arent SAD MAD study a human study? Why did the filing said the first inhuman will be in 27?
2
ErnieWorthing84
$MGTX So the new deck has 10 or so additional pages, on bota-vec. A lot of new emphasis throwing shade at Beacon--which, as far as I can find, is not offering up much data beyond it's primary endpoint, leaving us in the dark (pun intended) on other domains of vision.
2
shoc24
$MGTX reported earnings before the open today. GAAP EPS missed estimates: -$0.53 vs. -$0.50 expected, according to Stock Meadow.
StocktwitsEarnings
$MGTX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.53 up 14.52% YoY • Reported revenue of $4.81M up 1073.17% YoY • MeiraGTx estimates cash, receivables, the additional $95M Hologen upfront payment and associated reimbursements will fund operating expenses and capital expenditures into the second half of 2028; this excludes potential Lilly milestones and Royalty Note tranches.

Advertisement|Remove ads.